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ABSTRACT
Objcetives: Implantable cardioverter deﬁbrillators (ICDs)
are highly effective at preventing cardiac arrest, but their
availability is limited by high cost. Automated external deﬁ-
brillators (AEDs) are likely to be less effective, but also less
expensive. We used decision analysis to evaluate the clinical
and economic trade-offs of AEDs, ICDs, and emergency
medical services equipped with deﬁbrillators (EMS-D) for
reducing cardiac arrest mortality.
Methods: A Markov model was developed to compare the
cost-effectiveness of three strategies in adults meeting entry
criteria for the MADIT II Trial: strategy 1, individuals expe-
riencing cardiac arrest are treated by EMS-D; strategy 2,
individuals experiencing cardiac arrest are treated with an in-
home AED; and strategy 3, individuals receive a prophylactic
ICD. The model was then used to quantify the aggregate
societal beneﬁt of these three strategies under the conditions
of a constrained federal budget.
Results: Compared with EMS-D, in-home AEDs produced a
gain of 0.05 quality-adjusted life-years (QALYs) at an incre-
mental cost of $5225 ($104,500 per QALY), while ICDs pro-
duced a gain of 0.90 QALYs at a cost of $114,660 ($127,400
per QALY). For every $1 million spent on deﬁbrillators, 1.7
additional QALYs are produced by purchasing AEDs (9.6
QALYs/$million) instead of ICDs (7.9 QALYs/$million).
Results were most sensitive to deﬁbrillator complication
rates and effectiveness, deﬁbrillator cost, and adults’ risk of
cardiac arrest.
Conclusions: Both AEDs and ICDs reduce cardiac arrest
mortality, but AEDs are signiﬁcantly less expensive and less
effective. If ﬁnancial constraints were to lead to rationing of
deﬁbrillators, it might be preferable to provide more people
with a less effective and less expensive intervention (in-home
AEDs) instead of providing fewer people with a more effec-
tive and more costly intervention (ICDs).
Keywords: cost-effectiveness, deﬁbrillators, emergency med-
ical services, heart arrest, rationing.
Background
Health-care payors are increasingly caught in an eco-
nomic quagmire. On the one hand, they are besieged
by patients demanding coverage for new and expen-
sive therapies made available by successful biomedi-
cal research [1]. On the other hand, payors are
confronted by taxpayers and businesses who are
unwilling or unable to contribute ever more money
into the insurance pools to pay for these therapies
[2–4].
From a cost-effectiveness standpoint, this conun-
drum is evident in the highly effective and very expen-
sive new therapies that nevertheless have acceptable
cost-effectiveness ratios (e.g., $50,000–100,000 per
quality-adjusted life-year [QALY] gained). Such new
therapies are appealing to the individual patient who is
isolated from the true costs of treatment by insurance.
For society, however, providing ever larger numbers of
expensive, albeit cost-effective therapies to a growing
population of patients is contributing to the dramatic
increases in health-care expenditures that are currently
being observed [5,6]. Nowhere is the impact of this
“perfect storm” more apparent than the US Medicare
program where these expensive new therapies con-
verge with a growing elderly population to result in
unsustainable 10% annual spending growth for the
$391 billion program [7].
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The case of implantable cardioverter deﬁbrillators
(ICDs) for prevention of cardiac arrest highlights the
challenges confronting payors. Early studies with
stringent eligibility criteria demonstrated that ICDs
reduced cardiac arrest mortality in relatively small
populations of patients with severe congestive heart
failure (CHF) [8,9]. Subsequent economic evaluations
demonstrated that ICDs were also cost-effective for
these highly selected patient populations [10].
Because the absolute number of individuals meeting
these eligibility criteria was small, the absolute cost to
Medicare was limited. Nevertheless, more recent
studies have suggested that a far broader spectrum of
patients might receive clinical beneﬁt from ICDs
[11,12] and economic evaluations have demon-
strated ICDs to again be relatively cost-effective in
this broader population [13,14]. Medicare adminis-
trators have encountered difﬁculties in that the pro-
gram may not have sufﬁcient revenue to provide
ICDs to the estimated 500,000 Medicare beneﬁciaries
who currently qualify plus the estimated 40,000 new
patients each year who might beneﬁt from ICDs with-
out either a substantial increase in funding from the
federal government or dramatic reductions in Medi-
care expenditures in other areas––neither of which
are palatable options in the current political environ-
ment [15].
Automated external deﬁbrillators (AEDs) deployed
in the homes of individuals at high risk for cardiac
arrest represent a less expensive, albeit less effective,
alternative to ICDs. There are no published studies
directly assessing the effectiveness of in-home AEDs
and the NIH-funded Home Automatic External Deﬁ-
brillator Trial will not be complete for some time, but
available data from the public access deﬁbrillation
(PAD) literature suggest that in-home AEDs are likely
to be effective in this setting [16,17]. Traditionally, a
less effective therapy (AEDs) would be quickly dis-
missed in favor of a more effective therapy (ICDs)
under the assumption that the goal is to maximize the
beneﬁt afforded to the individual. Nevertheless, under
the conditions of budgetary constraint as Medicare is
now facing, it is possible to envision scenarios whereby
society would be better off by providing many individ-
uals with the less expensive therapy (AEDs) rather
than by providing fewer patients with the more expen-
sive option (ICDs).
In an effort to clarify these issues, we developed
a decision-analytic model to compare the cost-
effectiveness of prophylactic ICDs and in-home AEDs
with traditional emergency medical services equipped
with deﬁbrillators (EMS-D) available in most commu-
nities. We then conducted exploratory analyses to
examine the clinical and economic trade-offs that might
result if policymakers, faced with a ﬁxed national
budget for reducing cardiac arrest mortality, focused
their efforts on maximizing societal value.
Methods
Literature Review
Medline was used to search the 1966–2004 medical
literature using the terms heart arrest, emergency
medical services, public access deﬁbrillation, and
implantable cardioverter deﬁbrillator as were abstracts
of major scientiﬁc meetings from 2001–2004. Relevant
articles were abstracted by one of the authors (P.C.) to
obtain the values for the model. In cases where multi-
ple publications estimating a particular input were
available, we used the estimate from the study deemed
to be the most methodologically sound. If no single
study was superior, we took the mean of the available
estimates and used broad conﬁdence intervals in sen-
sitivity analysis.
Decision-Analytic Model
We constructed a Markov decision model by building
on our previous analyses assessing the cost-effective-
ness of AEDs [18]. The model took the societal per-
spective to evaluate the lifetime clinical and economic
impact of three alternative strategies for preventing
cardiac arrest in adults with CHF (Fig. 1): strategy
1–individuals experiencing cardiac arrest are treated
by EMS-D (EMS-D strategy); strategy 2––individuals
experiencing cardiac arrest at home are initially treated
with an in-home AED (AED strategy) followed by
EMS-D. Individuals who experience cardiac arrest out-
side their home do not have access to their AED and
receive treatment by EMS-D; strategy 3––all individu-
als receive a prophylactic ICD to prevent cardiac arrest
(ICD strategy). The model was populated with a
cohort of Medicare beneﬁciaries 65 years of age with
ischemic cardiomyopathy, ejection fraction less than
30% and meeting entry criteria for the MADIT II Trial
[11]. All model inputs are shown in Web Appendix 1.
All historical costs were adjusted from their
reported dollar value to 2004 dollars using an inﬂation
rate of 2.5% reﬂecting the consumer price index inﬂa-
tion rate between 1999 and 2002 [19]. All future costs
and beneﬁts were discounted at 3% annually in
accordance with the recommendations of the Panel on
Cost-effectiveness in Health and Medicine [10]. Tree-
AgePro decision analysis software (TreeAge Inc., Wil-
liamstown, MA) and Excel 2000 (Microsoft Inc.,
Redmond, WA) were used for all analyses.
Probabilities of Cardiac Arrest and Noncardiac 
Arrest Mortality
The initial annual mortality for patients assigned to
strategies 1 and 2 (11.2%) was derived from data from
patients randomized to medical therapy in the MADIT
II Trial (Web Appendix 1). This aggregate mortality
rate was split into cardiac arrest-related mortality
which was assumed to be reduced by in-home
AED availability (probability 5.7%) and noncardiac
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arrest-related mortality which was assumed not to be
improved by in-home AED availability (probability
5.5%) based on a secondary analysis of the MADIT II
Trial [20].
The initial probability of death for individuals
assigned to strategy 3 (ICD) was 8.2%; this aggregate
mortality was divided into cardiac arrest-related mor-
tality (2.2%) which is signiﬁcantly reduced by ICDs
relative to strategies 1 and 2, and noncardiac arrest-
related mortality (6.0%) which increases slightly with
ICDs relative to strategies 1 and 2 [20,21]. In subse-
quent years, overall mortality for all strategies was
assumed to increase based on life-table estimates [22].
Probabilities for EMS-D (Strategy 1) and In-Home AED 
(Strategy 2)
In strategy 1, all individuals suffering cardiac arrest,
irrespective of location, were treated by EMS-D. While
survival rates to hospital discharge of 25% have been
reported with optimized EMS-D, survival rates of 3%
to 5% are common in congested urban and remote
rural areas [23–29]; this variation reﬂects the fact that
survival falls by approximately 10% per minute delay
in deﬁbrillation [30]. In the base-case, 15% of cardiac
arrest victims were assumed to survive to hospital dis-
charge based on a time-to-deﬁbrillation interval of
approximately 10 minutes [31,32].
In strategy 2, all individuals were given an in-home
AED. The beneﬁt of an in-home AED is directly related
to any increase in survival that they confer by reducing
cardiac arrest mortality. Available evidence suggests
that 50% to 70% of out-of-hospital arrests occur at
home and that at least 50% are witnessed [33–37].
Even if an arrest occurs at home and is witnessed and
an AED is available, it is likely that sometimes the
device will not be used. In the base-case, it was
assumed that 50% of all arrests occurred at home and
that 40% of these arrests were witnessed and treated
with the in-home AED. No published studies have
examined the impact of in-home AEDs on cardiac
arrest survival, but studies examining the impact of
PAD on cardiac arrest survival are highly applicable
[16,17,38]. Based on these studies and a time-to-
deﬁbrillation interval of 5 minutes, cardiac arrest sur-
vival with an in-home AED was estimated to be 30%
in the base-case [30–32]. We took a conservative view
and assumed that an available in-home AED was used
exclusively for in-home cardiac arrests and that the
only person at risk of suffering an arrest was the indi-
vidual for whom the AED was prescribed.
Survivors of cardiac arrest in strategies 1 and 2 were
assigned to one of the three cerebral performance cat-
egories (CPC): CPC-1, unimpaired with no deﬁcit;
CPC-2, moderately impaired, but able to live inde-
pendently; CPC-3/4, severely impaired, requiring insti-
tutional care [39–43]. In the base-case, it was assumed
that all unimpaired and moderately impaired cardiac
arrest survivors received ICDs. Unimpaired survivors
with ICDs were assigned an annual mortality rate of
11% reﬂecting reports of survival of cardiac arrest vic-
tims with ICDs [44,45]. Severely impaired survivors
had an annual mortality of 30% based on long-term
survival of individuals with persistent vegetative states
(e.g., stroke, anoxic encephalopathy) [39,46]. We
assumed that moderately impaired arrest survivors
with ICDs had an annual mortality of 18%, between
unimpaired and severely impaired individuals.
Probabilities for ICD (Strategy 3)
The beneﬁt of an ICD (strategy 3) is directly related to
any increase in survival that is conferred relative to
medical therapy (strategy 1) or an in-home AED (strat-
egy 2). All individuals assigned to strategy 3 received a
prophylactic ICD, but had a 0.3% probability of death
during implantation [11,21,47,48]. Individuals were
at risk of requiring ICD generator replacement each
year, based on an estimated battery life of 5 years
[49,50], and had a 5% annual risk of developing an
ICD-related complication [47,48,51]. These complica-
tions were divided into minor complications (e.g., lead
malfunctions, need for device reprogramming; 90% of
all complications) and major complications (e.g., lead
fracture, pocket infection; 10% of all complications),
both of which were associated with a small probability
of patient death [47,48,51,52]. Individuals who devel-
oped their ﬁrst major complication were assumed to
require ICD replacement; a second major complica-
tion indicated failure of ICD therapy requiring ICD
removal and treatment with amiodarone, which
reduced total mortality by 13%, and an in-home AED
[53,54].
Costs for EMS-D and In-Home AED (Strategy 1 and 
Strategy 2)
Individuals assigned to strategies 1 and 2 incurred
annual costs of $10,000 for medical treatment of CHF
[49,55]. In addition, individuals in strategy 2 were
assigned additional costs related to their in-home
AED, including the purchase cost of AED, cost of AED
maintenance, and cost of AED training (Web
Appendix 1).
Costs for ICD (Strategy 3)
Individuals in strategy 3 incurred an initial cost of
$50,000 for elective hospitalization for ICD implanta-
tion and an annual cost of $10,000 for ongoing med-
ical care [49,51,56,57]. Although a cost of $50,000 for
elective ICD implantation is higher than some esti-
mates that have been published previously [13,56,58],
this higher value can be accounted for by the fact that
it includes the costs of the device, hospitalization for
implantation, and professional fees [51]. Costs for ICD
generator replacement, minor, and major complica-
tions were also included in the model [51,52]. All indi-
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viduals who experienced two major complications
failed ICD therapy and were assigned costs associated
with medical therapy plus an in-home AED.
Costs Related to Cardiac Arrest
Individuals who suffered cardiac arrest and were hos-
pitalized incurred a cost for the hospitalization; this
cost varied depending on whether the individual died
in the hospital or survived to discharge [49,59–62]. All
unimpaired arrest survivors were assigned future costs
based on published estimates of the costs of cardiac
arrest survivors [59,61]. Severely impaired survivors
were assumed to require institutionalization and costs
of care were based on costs of individuals who had suf-
fered disabling strokes [63]. As there are no published
data on the costs of future care for moderately
impaired cardiac arrest survivors, it was assumed that
costs were 25% greater than for unimpaired survivors
and this assumption was tested through sensitivity
analysis.
Utilities
The baseline utility of individuals with CHF was deter-
mined to be 0.88 based on a prior study by Tsevat
et al. using time trade-off measures to assess utilities in
patients with CHF who had survived myocardial inf-
arction [64]. Although numerous studies have assessed
the utility of individuals with CHF [64,65], it is
unclear whether receipt of ICDs increases or decreases
utility [56,57,66]. Based on available data, we
assumed that CHF patients with and without ICDs
had the same utilities (0.88) and this assumption was
evaluated through sensitivity analysis. Disutilities
related to ICD implantation, minor and major compli-
cations were represented by deducting the number of
hospital days required for treatment [51,66,67]. Utility
scores for unimpaired cardiac arrest survivors were
drawn from published studies [42,68]. Utility scores
for the moderately and severely impaired survivors
were estimated based on published data from stroke
survivors with similar levels of functional impairment
[69,70].
Sensitivity Analysis
Because of uncertainty regarding the precise values of
many of the model inputs, sensitivity analyses were
conducted for each input by allowing each parameter
to vary across the range of values identiﬁed in the med-
ical literature. Next, two-way sensitivity analyses were
conducted using combinations of model variables.
Finally, Monte Carlo simulation, which allows all var-
iables to vary simultaneously, was conducted to fur-
ther assess the robustness of our ﬁndings [71]. For this
analysis, each input was allowed to vary across the
entire range of potential values identiﬁed in the litera-
ture review (Web Appendix 1); variables related to
costs were assigned log-normal distributions, while all
others were given normal distributions [72].
Societal Impact of Alternative Distribution Strategies
In the ﬁrst distribution analysis, a national budget for
cardiac arrest prevention in Medicare beneﬁciaries was
established and “capped” at 2002 ICD expenditure lev-
els and model was used to evaluate the clinical and eco-
nomic trade-offs of each of the three strategies. In the
second analysis, the results of the model were “ﬂipped”
from the typical “cost per QALY gained” reported in
most cost-effectiveness analysis to results based on the
QALYs gained per $million spent—an alternative
measure of the societal value of available strategies
where expenditures are limited to a ﬁxed budget.
Results
Cost-Effectiveness: Base-Case
Providing in-home AEDs to all adults with CHF and
an ejection fraction of less than 30% (strategy 2)
resulted in a gain of 0.05 QALYs at an incremental
cost of $5225 relative to EMS-D alone (strategy 1),
resulting in a cost per QALY gained of $104,500
(Table 1). Alternatively, providing all individuals with
ICDs (strategy 3) resulted in a gain of 0.90 QALYs at
an incremental cost of $114,660 relative to strategy 1,
resulting in a cost per QALY gained of $127,400. Pro-
viding individuals with ICDs instead of AEDs resulted
in a gain of 0.85 QALYs at an incremental cost of
$109,435, resulting in an incremental cost-effective-
ness ratio of $128,800 per QALY.
One-Way Sensitivity Analyses
In one-way sensitivity analysis (Web Appendix 2), the
cost-effectiveness of in-home AEDs was sensitive to the
Table 1 Cost-effectiveness of in-home AEDs and ICDs compared with EMS-D
Strategy Cost ($)
Life-years
gained
Effectiveness
(QALYs)
Incremental
Cost* ($)
Incremental
effectiveness*
(life-years)
Incremental
effectiveness*
(QALYs)
Cost per
QALY
gained* ($)
EMS-D 75,305 6.59 5.76 Na Na Na Na
AED 80,530 6.66 5.81 5,225 0.07 0.05 104,500
ICD 189,965 7.73 6.66 114,660 0.98 0.90 127,400
*Compared with EMS-D.
AED, automated external deﬁbrillator; EMS-D, emergency medical services equipped with deﬁbrillator; ICD, implantable cardioverter deﬁbrillator; Na, not available; QALY,
quality-adjusted life-year.
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probability that an in-home AED was used and the pur-
chase cost of the in-home AED. In addition, the cost-
effectiveness of AEDs and ICDs was sensitive to the
probability of cardiac arrest; AEDs remain undomi-
nated by ICDs so long as the annual probability of car-
diac arrest was less than 8% per year (Fig. 2). The
incremental cost-effectiveness of ICDs relative to AEDs
fell below $100,000 per QALY when the annual risk of
cardiac arrest was 8% or greater, but never fell below
$50,000; thus, ICDs weakly dominated AEDs when
the probability of cardiac arrest exceeded 8% per year.
The cost-effectiveness of AEDs was also sensitive to
changes in the absolute survival beneﬁt that the AED
afforded relative to EMS-D care (Fig. 3). In the base-
case, it was assumed that cardiac arrest survival
increased from 15% with EMS-D to 30% with an
AED; as the probability of survival with an in-home
AED increased from 20% to 50% (holding survival
with EMS-D constant at 15%), the cost per QALY
gained of AEDs, relative to EMS-D, declined from
$230,500 to $68,500.
In one-way sensitivity analysis, the cost-effective-
ness of ICDs relative to EMS-D was sensitive to the
annual probability of ICD-related complications and
the effectiveness of ICDs in reducing cardiac arrest
mortality. For example, as the annual risk of ICD-
related complications increased from 1% to 10%, the
cost per QALY gained increased from $78,000 to
$189,000. As the relative risk reduction of cardiac
arrest afforded by an ICD decreased from 80% to
30%, the cost per QALY gained increased from
$86,800 to $477,500 (Fig. 4). The cost-effectiveness of
ICDs was also somewhat sensitive to reductions in the
cost of ICD implantation; as the cost of elective ICD
implantation was reduced from $60,000 to $20,000,
the cost per QALY gained decreased from $159,800 to
$95,000.
Multi-Way Sensitivity Analysis
In Monte Carlo simulation, the median incremental
cost-effectiveness for in-home AEDs and ICDs com-
pared with EMS-D were $93,200 per QALY (mean
$119,000 [interquartile range: $76,200 to $121,800])
and $131,000 per QALY (mean $133,200 [interquar-
tile range: $104,800 to $158,300]), respectively.
Societal Impact of Alternative Distribution Strategies
First, it was necessary to estimate 2002 ICD-related
expenditures. This was done by multiplying the
number of Medicare beneﬁciaries who received ICDs
in 2002 (40,000) by the lifetime cost of an ICD
($114,660) as calculated by our decision model; this
resulted in a budget of $4.58 billion for deﬁbrillators
in 2002. This budget could be used to purchase 40,000
ICDs (as was done in 2002) or 876,000 AEDs. Pro-
Figure 2 One-way sensitivity analysis involving probability of cardiac
arrest. AED, automated external deﬁbrillator; ICD, implantable cardio-
verter deﬁbrillator; QALY, quality-adjusted life-year.
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viding 40,000 individuals with ICDs would be likely to
produce 36,000 QALYs, while 876,560 individuals
with AEDs would result in a gain of 43,830 QALYs
(Table 2). Thus, at equivalent costs, home AEDs pro-
vide a greater population-wide gain in QALYs. Alter-
natively, for every $million spent on reducing cardiac
arrest mortality, 1.7 additional QALYs are produced if
AEDs are purchased (9.6 QALYs/$million) instead of
ICDs (7.9 QALYs/$million).
Discussion
Interpretation of the results of our analysis is complex.
ICDs are substantially more effective (6.66 QALYs per
person) than either AEDs (5.81 QALYs) or EMS-D
(5.76 QALYs) and have a similar cost-effectiveness
ratio to AEDs when compared with EMS-D ($127,400
per QALY for ICDs; $104,500 for AEDs); from a tra-
ditional cost-effectiveness perspective, this would
make ICDs the preferred technology in most circum-
stances. Nevertheless, in an era of increasingly con-
strained federal budgets and growing population of
patients at risk for cardiac arrest, our exploratory
analyses are provoking. From this perspective, society
might reap similar or greater value from using
resources to provide the less effective but less expen-
sive AEDs (9.6 QALYs per $1 million) to many
patients as opposed to providing far fewer patients
with the more effective but more expensive ICDs (7.6
QALYs per $1 million), as was envisioned by Kent
et al. when proposing a role for “decremental cost-
effectiveness” [73].
The challenges of shifting from a strategy of maxi-
mizing QALYs gained per person to one of maximizing
QALYs per dollar in expenditures would be signiﬁ-
cant. Adoption of such a strategy would require a deci-
sion by legislators and the public that rationing of
health care is necessary in some form [74]. Although
rationing is explicit in many countries [75,76], efforts
to make the process opaque in the United States have
routinely failed [77].
Even if rationing of expensive medical technolo-
gies such as ICDs were accepted as necessary, imple-
menting such a strategy would be difﬁcult. One
method might involve a three-tiered system for reduc-
ing cardiac arrest mortality. Individuals at low or
moderate risk for cardiac arrest could be treated with
conventional medical therapy supplemented by EMS-
D. Individuals at high risk might be given an in-home
AED, while individuals at highest risk would be
given ICDs. Implementing such a strategy would ﬁrst
require determining an available budget for reducing
cardiac arrest mortality. Next, analysts would need to
determine the distribution of risk among the popula-
tion and then decide how many ICDs and AEDs
should be purchased to maximize the value to society
subject to budgetary constraints. Finally, decision
rules would need to be developed to allow clinicians
to accurately assess each individual’s risk and make
treatment recommendations.
Following such a strategy of risk-based prevention
of cardiac arrest would have certain advantages. First,
available data suggest that patients at the highest risk
for cardiac arrest receive the greatest beneﬁt from
ICDs, making ICDs most cost-effective in this patient
population. Second, such a strategy would allow soci-
ety to provide AEDs to hundreds of thousands of indi-
viduals at increased risk for cardiac arrest each year,
who do not qualify for ICDs including individuals
with diabetes and hypertension [78].
Alternative strategies that are informed by cost-
effectiveness analysis should also be considered. For
example, payors might consider making a deﬁned
monetary contribution for each patient with cardiac
arrest risk factors; then, the patient and their providers
could jointly decide how to allocate that money (i.e.,
patients choose EMS-D and pocket the contribution of
their payor, or choose an AED or ICD and pay for any
amount above the payor’s contribution). Alternatively,
payors might adopt the so-called “beneﬁt-based
copay” where individuals at highest risk for cardiac
arrest would have minimal copays for ICDs while
individuals at lower risk would face larger copays
[79]. Implementation of any strategy based on cost-
effectiveness would need to take into account limita-
tions in the methodology. In particular, policymakers
would need to insure that any such system takes into
account the importance of patient preferences for the
various interventions that cannot be accounted for by
the models.
In interpreting our results, it is important to recog-
nize that our assumptions regarding the effectiveness
of AEDs were deliberately conservative. For example,
the model assumed that an in-home AED would be
Table 2 Societal impact of “capping” deﬁbrillator expenditures
Budget ($)
Incremental cost
per device* ($)
QALYs
gained
Devices 
purchased
Total QALYs
gained
AEDs 4,580,000,000 5,225 0.05 876,560 43,830
ICDs 4,580,000,000 114,380 0.90 40,000 36,000
*Lifetime incremental cost compared with EMS-D based care.
AED, automated external deﬁbrillator; EMS-D, emergency medical services equipped with deﬁbrillator; ICD, implantable cardioverter deﬁbrillator; QALY, quality-adjusted
life-year.
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used only on the individual for whom the device was
purchased, but recent data have demonstrated that in
actuality, in-home AEDs are used on visitors and fam-
ily members [80]. In addition, we assumed that AEDs
were used only at home and were never used outside
the home, despite the fact that AEDs are portable [81].
The analysis also failed to include passive beneﬁts
(a.k.a. reassurance value) that in-home AEDs might
provide [82]. Finally, by purchasing 500,000 AEDs per
year, in a matter of years, the country could be “blan-
keted” with devices, thus truly moving PAD from an
abstraction to a reality. All of these factors would add
to the value of AEDs.
The results of the current study should be consid-
ered in light of other recent economic evaluations of
ICDs that have also been based on data from the
MADIT II Trial (Table 3). We found ICDs to be both
less effective and more expensive than a number of
prior studies [13,14,51]; this appears to be due to a
number of small but signiﬁcant differences among the
models. First, our model assumed that ICDs reduce car-
diac mortality but slightly increased noncardiac mor-
tality, an assumption that is supported by prior studies
[20,21,83]. Second, our model more comprehensively
accounted for the incidence and costs of ICD-related
complications than prior studies [14]. Inclusion of such
complications is important, as evinced by the recent
high-proﬁle recalls of tens of thousands of AEDs by
device manufacturers after revelation of device mal-
functions [84,85]. Third, we assumed that ICDs were
slightly more expensive than some of the other analy-
ses. Accounting for these differences reduced the dis-
crepancy between the results of our analysis and those
of Sanders et al., but did not eliminate them; this
underscores the importance of transparency in report-
ing decision analysis and adhering to guidelines [10]. It
is also important to recognize that the cost-effective-
ness of ICDs would be reduced if ICDs prove less effec-
tive in general practice than in clinical trials or if
coverage is expanded to patients at lower risk for car-
diac arrest. Finally, it is important to recognize that
over time technology is likely to improve resulting per-
haps in both improved effectiveness of AEDs and ICDs
as well as reductions in cost that are likely to change the
balance between these devices.
The current study has a number of limitations.
First, the model was populated with a cohort of
patients with ischemic cardiomyopathy and an ejection
fraction of less than 30% meeting entry criteria for the
MADIT II Trial; the model relied on published data
regarding the average cardiac arrest and noncardiac
arrest mortality rates from the trial despite the fact that
there was certainly a distribution of mortality rates
based on clinical risk factors (e.g., ejection fraction).
Using a single point estimate limited our ability to pre-
cisely determine actual, cardiac arrest mortality rate
thresholds where it might be cost-effective to advocate
one strategy (e.g., ICDs) versus another (e.g., AEDs).
In this respect, future studies pooling the results of the
growing number of ICD primary-prevention trials to
provide accurate estimates of risk distribution among
patient populations would be most useful. Second, the
cost-effectiveness of ICDs is sensitive to the annual
probability of ICD-related complications, yet data on
such complications are limited. Third, our analysis did
not capture potential complications resulting from in-
home AED deployment, but this appears to be justiﬁed
based on the safety record of modern AEDs; the ongo-
ing Home Use AED trial will help to clarify the fre-
quency of such complications. Fourth, if the costs of
ICDs decline, some of the budgetary pressure might be
reduced. Fifth, a risk-based cardiac arrest prevention
strategy is dependent on our ability to identify speciﬁc
risk factors (e.g., T-wave alternans) for cardiac arrest
in individual patients [86].
In summary, ICDs have the potential to dramati-
cally reduce mortality in a broad spectrum of patients
with cardiac dysfunction. The key to unlocking this
potential lies in making these devices available to the
patient populations who stand to receive the largest
beneﬁt, without hampering payors’ abilities to cover
both currently available therapies and future techno-
logical innovations.
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